We read with interest the well-balanced Comment by Zheng and colleagues (COVID-19 and the cardiovascular system. *Nat. Rev. Cardiol*. **17**, 259--260; 2020)^[@CR1]^ and their Reply (Reply to: 'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19'. *Nat. Rev. Cardiol*. **17**, 313--314; 2020)^[@CR2]^ to the Correspondence written by Mourad and Levy (Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. *Nat. Rev. Cardiol*. **17**, 313; 2020)^[@CR3]^.

We have reported the capacity of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) to increase the left ventricular levels of *Ace2* mRNA when given to normotensive rats either under normal conditions^[@CR4]^ or following coronary artery ligation^[@CR5]^. This work revealed the existence of a negative feedback mechanism in which the angiotensin-converting enzyme 2 (ACE2)--angiotensin-(1--7)--Mas receptor axis counterbalances the pathological effects of angiotensin II^[@CR6]^. In their Reply^[@CR2]^, Zheng and colleagues suggest that the mechanism underlying the increase in levels of cardiac *Ace2* mRNA and ACE2 activity by these drugs was undetermined; we wish to clarify that we did elucidate the mechanism by which these medications augment the expression of ACE2 (refs^[@CR7]--[@CR9]^).

In these studies, the inhibitory effect of angiotensin II on the transcription of *Ace2* in cultured cerebellar or medullary astrocytes from rats was prevented by exposure to losartan or valsartan but not PD123319 (a blocker of angiotensin II receptor type 2)^[@CR7]^. A similar finding was obtained in cultured cardiomyocytes and cardiac fibroblasts from neonatal rats^[@CR8]^; in these in vitro experiments, the inhibitory effect of angiotensin II on the transcription of *Ace2* and on ACE2 enzymatic activity was replicated by the treatment of cardiomyocytes with exogenous endothelin 1 (ref.^[@CR8]^). The inhibitory effect of angiotensin II on *Ace2* transcription is mediated by activation of extracellular signal-regulated kinase 1 (ERK1; also known as MAPK3) and ERK2 (also known as MAPK1)^[@CR8],[@CR9]^. In addition, treatment of rat neonatal cardiomyocytes in vitro with atrial natriuretic peptide reversed the downregulation of *Ace2* transcription induced by angiotensin II or endothelin 1 (ref.^[@CR8]^). We have also shown that angiotensin II reduces *Ace2* transcription and ACE2 activity in rat aortic smooth muscle cells in vitro via activation of a MAPK phosphatase pathway^[@CR9]^, as confirmed by others^[@CR10]^.

These experiments show that *Ace2* expression in cardiac tissues in rats depends on the balance and concentration of regulatory molecules. We appreciate the opportunity to highlight the cellular signalling mechanisms by which ARBs increase *Ace2* expression and ACE2 activity, especially given that ACE inhibitors and ARBs have opposite effects on the plasma and tissue concentrations of angiotensin II and angiotensin-(1--7) (ref.^[@CR6]^).
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